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1 | INTRODUCTION

to 45 days) after hospital discharge.8,9,12–16 Despite this well-established association,8–10 there are few data specifically addressing

The coronavirus disease 2019 (COVID-19), first identified in

VTE in patients recently hospitalized with COVID-19 infections.17,18

December 2019 in Wuhan, China, is a major public health crisis with

Indeed, infection-associated VTE might account for a substantial

new infections increasing exponentially worldwide.1 COVID-19 is an

burden of incident or recurrent VTE among those with COVID-19.

acute infectious disease caused by the severe acute respiratory syn-

In addition, small-vessel hyaline thrombus formation has been de-

drome coronavirus 2 (SARS-CoV2) and has contributed to significant

scribed in autopsies of patients with COVID pneumonia.19 There is

morbidity and mortality, including the development of coagulopa-

increasing concern that mortality seen across all age groups may be

thy. 2 Similar thrombotic and thromboembolic events have occurred

secondary to PE, as 31% incidence of thrombotic complications in

during other viral outbreaks, including severe acute respiratory syn-

ICU patients with COVID-19 infections is recently reported. PE was

drome (SARS), Middle Eastern respiratory syndrome, and influenza

the most frequent thrombotic complication and contributed to 81%

A H1N1.

3–7

of thrombotic complications. 20 To improve outcomes, targeted pro-

Venous thromboembolism (VTE) (ie, deep vein thrombosis or

phylaxis efforts to improve coagulopathy and reduce incident VTE in

pulmonary embolism [PE]) is a common complication of acute infec-

patients with acute infectious diseases, specifically COVID-19, may

tious diseases, which increase VTE risk 2-fold to 32-fold.8–10 Survival

be advantageous.

among patients with incident and recurrent VTE is significantly re-

Currently, VTE prophylaxis duration is mainly limited to the pe-

duced, especially after PE.11 Hospitalized patients with acute medi-

riod of hospitalization, 21 but most VTE events occur within the first

cal illness, including infections such as pneumonia, are at increased

month following hospital discharge. 22 Recent data support the find-

risk of VTE, both in-hospital and for an extended period of time (up

ing that an elevated D-dimer (>2× upper limit of normal [ULN]) is an
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important novel biomarker in identifying a high-VTE-risk population

are several risk stratification tools available (eg, the Caprini,

that would benefit from extended thromboprophylaxis, an observa-

IMPROVE [International Medical Prevention Registry on Venous

tion that is especially important in the hospitalized COVD-19 pop-

Thromboembolism], and Padua models) to assist the health care

ulation. 23 If all hospitalized patients received universally effective

provider in assessing VTE risk among hospitalized patients.31–34

prophylaxis, one quarter of the VTE burden in the community would

Regardless, the ISTH guidelines recommend prophylactic dose of

be prevented.

24

To further reduce the VTE burden, better prophy-

laxis strategies are needed, which include prolonging VTE prophylaxis beyond hospital dismissal.

low-molecular-weight heparin (LMWH) in all hospitalized COVID patients (including non-ICU) unless contraindicated.35
For parenteral anticoagulants, there is in vitro evidence that

There are several concerns linked to the VTE prevention in

coronavirus may use the sulfated, negatively charged heparan sulfate

COVID-19 patients: How can we limit the risk of VTE among pa-

as the initial receptor for target cells (even in the absence of angio-

tients who are hospitalized? Do we use similar prophylaxis in the

tensin converting enzyme 2 [ACE2]).36 ACE2 is an enzyme attached

common medical ward and in the intensive care unit (ICU)? How do

to the outer surface on cell membranes within the lungs, arteries,

we manage patients with COVID-19 who are already taking oral an-

heart, kidney, and intestines and serves as the entry point into cells

ticoagulants or antiplatelets?

for some coronaviruses.37–40 There is a suggestion from in vitro evi-

To address these concerns, several leading national and inter-

dence that LMWH may competitively bind to coronavirus. Heparins

national health care institutions have developed protocols to help

as a class may suppress the cytokine storm induced by activated T

guide health care professionals on how to manage thrombotic and

cells, macrophages, and monocytes/neutrophils, all with increased

antithrombotic therapy related to COVID-19 during this pandemic.

IL expression (including IL-2R/6).41 Empiric evidence supports use of

Currently, there is significant variability in expertise, as many of the

treatment dose unfractionated heparin (UFH) as improving throm-

existing protocols derived are from sporadic reports and small ret-

bosis-free survival in acute respiratory distress syndrome with in-

rospective studies. Given the lack of large prospective cohorts, the

fluenza A H1N1 but not coronavirus.42 There is also recent evidence

current document represents an effort to provide several simple

that prophylactic doses of LMWH (namely, enoxaparin at 40-60 mg

and easy-to-follow algorithms to be considered as an interim clinical

subcutaneous [s.c.] daily) or UFH (10 000-15 000 units/d) appears

guidance since the knowledge and therapeutics in managing COVID-

to be associated with better prognosis in COVID-19 patients with

19 is rapidly evolving. The aim of this document is to provide clini-

serious illness meeting sepsis-induced coagulopathy score of ≥4 or

cians and hospital systems a template on safe and effective use of

with markedly elevated D-dimer (>6× ULN) compared to non–hepa-

antithrombotic medications in health care systems affected by the

rin users.43 The World Health Organization interim guidance state-

COVID-19 pandemic from an institutional perspective, including

ment as well as a recent guidance statement from ISTH recommends

post–hospital discharge prophylaxis.

prophylactic use of daily LMWH over twice-daily subcutaneous
UFH.44,45

1.1 | Role of COVID-19 and antithrombotic
considerations

Obese patients with body mass index (BMI) >30 kg/m2 have
increased risk of VTE,46 recurrent VTE,47 and postthrombotic syndrome 48; however, prior studies have mainly focused VTE prophylaxis on extreme obesity defined by BMI >40 kg/m2. As the

Patients with COVID-19 and underlying cardiovascular disease and

distribution of LMWH is weight based, the efficacy of standard doses

comorbidities have greater morbidity and mortality from COVID-

may be decreased due to the effects of plasma drug distribution

19. 25,26 Common laboratory abnormalities include lymphopenia

and pharmacokinetics in obese individuals.49 Furthermore, in a sub-

and increase in lactate dehydrogenase and inflammatory markers

group analysis of obese patients from the PREVENT (Prevention of

such as C-reactive protein, D-dimer, ferritin, interleukin (IL)-6, and

Recurrent Thromboembolism) trial, dalteparin lost its thrombopro-

fibrinogen. 27,28 Thrombocytopenia29 and increased D-dimer levels30

phylactic benefit in patients with BMI >35 kg/m2.50 The ITOHENOX

are the most consistent laboratory abnormalities associated with a

(Adjusted Value of Thromboprophylaxis in Hospitalized Obese

higher risk of developing severe COVID-19. Therefore, several pro-

Patients: A Comparative Study of Two Regimens of Enoxaparin)

tocols suggest measuring D-dimers, prothrombin time, and platelet

study shows in medically obese inpatients that thromboprophylaxis

counts to help assess COVID-19 severity. Whether the very elevated

with enoxaparin 60 mg provides higher control of anti-Xa activity,

D-dimers seen in very sick COVID-19 patients represent severe co-

without more bleeding complications than the standard enoxaparin

agulopathy or are markers of a severe inflammatory “cytokine storm”

regimen.51

is not known.

Based on these observations and guidance, several of the protocol strategies suggest the use of thromboprophylaxis with LMWH at

1.1.1 | In-hospital VTE prophylaxis

prophylactic or intermediate doses (ie, 40 mg s.c. daily or 40 mg s.c.
twice daily, especially for BMI > 30 kg/m2) as the preferred agent
over UFH, unless patients have severe renal insufficiency (creat-

Hospitalized patients with acute medical illness, including COVID-

inine clearance [CrCl] < 30 mL/min or even 15 mL/min) (Table 1).

19, should have an assessment of VTE versus bleeding risk. There

This strategy avoids the increased health care worker exposure, use
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Comparisons of different institutional protocols proposed in United States and France in case of COVID-19
Froedtert Health & The Medical College of
Wisconsin, USA

Northwell Health, USA

Northshore University Health System, USA

Which patients?

In- and outpatients

Inpatients

In- and outpatients

Thrombotic risk

Yes

Yes

Yes

Use of Wells’ Criteria

Use of ISTH DIC score

Use of ISTH DIC score

IMPROVE VTE score

IMPROVE VTE score

D-dimer

D-dimer

Not mentioned

Not mentioned

Yes

Yes

Yes

Not mentioned

Patients hospitalized with suspected or confirmed

Suggestion of the use of thromboprophylaxis

For moderate to severe with DIC and

assessment
Criteria for VTE
risk

Hemostasis
surveillance
Assessment of
bleeding risk
Proposed
prophylactic

COVID-19, VTE prophylaxis with enoxaparin at

with enoxaparin at prophylactic or

no overt bleed, consider intermediate

treatments

prophylactic or intermediate doses (ie, 40 mg

intermediate doses (ie, 40 mg s.c. daily

dose of LMWH

s.c. daily or 40 mg s.c. twice daily, especially for

or 40 mg s.c. twice daily, especially for

BMI > 40 kg/m2) as the preferred agent over

BMI > 30 kg/m2) as the preferred agent

UFH, unless patients have acute renal failure

over UFH, unless patients have severe

or chronic kidney disease (CrCl < 15 mL/min); if

renal insufficiency (CrCl < 15 mL/min); if

CrCl < 15 mL/min, then UFH 5000 IU s.c. 3 times

CrCl < 15 mL/min, then UFH 5000 IU s.c. 3

daily for BMI < 40 kg/m2 or 7500 IU s.c. twice

times daily for BMI < 30 kg/m2 or 7500 IU

daily for BMI > 40 kg/m2

s.c. 3 times daily for BMI > 30 kg/m2
Multimodal thromboprophylaxis with

VTE prophylaxis with daily LMWH, or twice daily

pharmacologic + mechanical compression

subcutaneous UFH is strongly recommended

should be used in ICU settings

(LMWH may be advantageous to reduce PPE
use and provider exposure)

Extended VTE prophylaxis with rivaroxaban

Patients hospitalized with COVID-19,

Continue postdischarge prophylaxis to all

10 mg p.o. daily for 30 d should be considered at

especially those with an IMPROVE VTE

patients with COVID-19 over 50 y old; consider

hospital discharge, without bleeding risk factors;

score of ≥4 or over 60 y and with elevated

extending prophylaxis to 6 wk rivaroxaban or

if D-dimer is > 2× ULN during the hospitalization

D-dimers and without bleeding risk factors,

betrixaban in patients with any additional risk

and Previous VTE or ≥2 of the following

should be strongly considered for extended

factor: prior history of thrombosis, ICU stay,

characteristics are met: Age > 60, ICU stay,

thromboprophylaxis up to 39 d after hospital

cancer, thrombophilia, paralysis

current lower limb paralysis or paresis, current

discharge with either enoxaparin 40 mg s.c.

cancer, known thrombophilia

daily or rivaroxaban 10 mg p.o. daily
For outpatients diagnosed with mild or moderate

Patients with a CrCl <30 mL/min were excluded
from the clinical trials of extended prophylaxis;

COVID-19 and low risk of bleeding, consider

therefore, the risk and benefit in this patient

VTE prophylaxis as above

population is not known and extended prophylaxis
is not recommended

Patients with

Assuming no contraindications, DOACs are

If possible, patients may be switched

Assuming no contraindications, DOACs preferred

long-term

considered first line for anticoagulation for most

to dabigatran as the DOAC of choice;

to coumadin for chronically anticoagulated

anticoagulation

patients and preferred to coumadin. Alternatively,

alternatively, dose-adjusted warfarin with

COVID-19 outpatients

dose-adjusted warfarin with extended INR

extended INR monitoring should be an

monitoring should be an option

option

Lower limb

As usual; not systematic

Not mentioned

Not mentioned

ultrasound exam

BMI, body mass index; COVID-19, coronavirus disease 2019; CrCl, creatinine clearance; DIC, disseminated intravascular coagulation; DOAC,
direct oral anticoagulant; GFR, glomerular filtration rate; ICU, intensive care unit; INR, International Normalized Ratio; LMWH, low-molecularweight heparin; NA, not available; PPE, personal protective equipment; s.c., subcutaneous; UFH, unfractioned heparin; IU, international units; ULN,
upper limit normal; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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University Hospital of SaintUniversity hospital of Amiens, FRA

University hospital of Montpellier, FRA

University Hospital of Rennes, FRA

Etienne, FRA

Outpatients

In- and outpatients

Inpatients and elderly in establishment

ICU patients

Yes

Yes

Not mentioned

Not mentioned

Immobilization > 48 h, cancer,

Thrombotic risk and ISTH DIC score

NA

NA

Not mentioned

Yes

Yes

Yes

Not mentioned

Yes

Yes

Not mentioned

Patients with COVID-19 with at

For all inpatients: enoxaparin 4000 IU/d for at

For all hospitalized patients except with

If BMI > 30 kg/m2 or severe

recent surgery, personal history
of VTE, BMI > 30 kg/m2,
age > 70 y old

least 1 VTE risk factor will receive

least 14 d

thrombosis prophylaxis with

bleeding syndrome and BMI < 30 kg/m2:

inflammatory syndrome or femoral

enoxaparin 4000 IU/d

venous catheter: Enoxaparin

LMWH for at least 10 d (auto-

6000 IU/d

injection should be preferred)

For outpatients with elevated D-dimers (>2 N) or

For all hospitalized patients except with

with VTE risk factors (personal history of VTE,

bleeding syndrome and BMI 30-40 kg/

known thrombophilia, lower limb paralysis, active

m2: enoxaparin 6000 IU/d

If BMI > 40 kg/m2: enoxaparin
4000 IU × 2/d

cancer, immobilization > 7 d, age > 60 y old):
enoxaparin 4000 IU/d for at least 14 d
If GFR < 30 mL/min (Cockroft): UFH 5000 IU × 2/d

For all hospitalized patients except with
bleeding syndrome and BMI > 40 kg/m2:

If CrCl < 30 mL/min: calciparin
0.2 mL × 3/d

enoxaparin BMI × 2/d (eg BMI = 42 kg/
m2), then enoxaparin 4000 IU × 2/d

If BMI ≥ 40 kg/m2: Enoxaparin 4000 IU × 2/d

For all hospitalized patients except with
bleeding syndrome and GFR < 15 mL/
min: tinzaparin 3500 IU/d (we do not
suggest use of calciparin 0.2 mL × 3/d to
avoid accumulation

If high bleeding risk: discuss preventive
anticoagulation; if hospitalized patients:

In ICU patients: proceed as for hospitalized
patients

compression bands (BIFLEX) if no peripheral
artery disease; in ICU patients: intermittent
pneumatic compression
In elderly patients in establishment:
enoxaparin 4000 IU/d
Not mentioned

In hospitalized patients: replace by LWMH (in the

Not mentioned

Not mentioned

As usual; not systematic

Fast (4 points):

absence of contraindication)

Not mentioned

As usual; not systematic

• Systematic at days 7, 14, and 21
• Earlier if patient gets worse
without any evident cause
• Earlier if femoral venous catheter
• Before first chair setting
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of limited resources such as personal protective equipment for fre-

groups. Patients hospitalized for COVID-19 would meet criteria

quent blood draws, and the time needed to achieve therapeutic acti-

similar to these trials as an infectious disease. There is recent evi-

vated partial thromboplastin times. There are randomized trials that

dence that an IMPROVE score of ≥4 (Table 2) ± elevated D-dimer

are being initiated studying intermediate to high doses of LMWH

(>2× ULN) identifies a >3-fold higher VTE risk population that signifi-

in the management of patients with COVID-19 with severe illness.

cantly benefit from extended out-of-hospital thromboprophylaxis
up to 39 days or more with rivaroxaban without an increase in major
bleeding.12,23,34 There are also data with betrixaban that reveal net

1.1.2 | Antithrombotic use with antivirals

clinical benefit from extended thromboprophlaxis for up to 42 days
in hospitalized medically ill patients, including those with severe in-

It is important to recognize the interactions that may occur between

fection.56 Further, prolonged rivaroxaban prophylaxis reduced the

COVID-19 investigational therapies and antithrombotic use. If new

incidence of VTE in patients hospitalized for acute infectious dis-

medications are added to treat COVID-19 or other conditions, drug

eases, particularly those involving the lungs. Efficacy benefits were,

interaction checking should be completed due to the risk of inter-

in part, offset by bleeding outcomes.57 Identification of independent

action with antithrombotic medications through P-glycoprotein

VTE risk factors and estimating the magnitude of the associated risk

(P-gp) or the cytochrome 450 (CYP) system in the liver (especially

may be helpful when strategies for prophylaxis delivery are devised.

CYP3A4). Several protocol strategies take into consideration the

Alternatively, consider risk-benefit evaluation for extended enoxa-

concomitant use of antithrombotic with antiviral therapies (espe-

parin in selected patients.58 Protocols suggest patients hospitalized

cially with the antivirals liponavir and ritonavir), as this can affect

with COVID-19, especially those with an IMPROVE VTE score of

choice and/or dosage of antiplatelet and anticoagulants. For anti-

≥4, elevated D-dimer (>2× ULN), and ≥2 of the following charac-

platelet agents, certain antivirals, especially lopinavir/ritonavir, may

teristics are met: age > 60, previous VTE, current cancer, or known

potentiate CYP3A4 or P-gp inhibition, and as such there may be

thrombophilia, should be strongly considered for extended throm-

reduction in clopidogrel effects and increased effects of ticagre-

boprophylaxis up to 39-45 days after hospital discharge with either

lor.52,53 Therefore, these agents should be switched over to prasug-

lovenox 40 mg s.c. daily or rivaroxaban 10 mg p.o. daily and low risk

rel if possible (unless there are contraindications such as prior stroke

of bleeding. 23,58 Insurance coverage investigation should be started

or transient ischemic attack).53 Alternatively, platelet function stud-

early during acute hospital stay to ensure patient affordability.

ies (P2Y12 monitoring) may also be considered.

Consideration for prophylaxis should also include high-risk patients

For oral anticoagulants (OACs), drug interactions should be con-

with COVID-19, including those with limited mobility, history of prior

sidered with direct oral anticoagulants (DOACs (P-gp or moderate to

VTE, active malignancy, and BMI > 30 kg/m2 requiring supplemental

strong CYP3A4, either inhibitors or inducers). Apixaban and rivarox-

oxygen or recent stay in the ICU. All individuals are advised to stay

aban have CYP3A4 and P-gp inhibition while dabigatran and edox-

active, if able, during times of quarantine.

aban have only P-gp inhibition. Betrixaban has P-gp and ATP-binding
cassette subfamily B member 1 inhibition.54 Dose adjustments may
be required if using vitamin K antagonists (VKAs), apixaban, or betrixaban, while adjustments are not needed for edoxaban and ri-

1.1.4 | Continuation of home antithrombotic
medications or need of chronic antithrombotic use

varoxaban. Parenteral anticoagulants, including UFH or LMWH,
are non-CYP metabolized and do not interact with investigational

Evaluating choice of anticoagulant is always important to ensure

agents, while edoxaban and rivaroxaban should not be coadminis-

that the patient is on optimal therapy. Several protocol strategies

tered with lopinavir/ritonavir. Currently, patients with COVID-19

suggest that patients on chronic antithrombotics (antiplatelets or

treated with IL-6 inhibitors, such as tocilizumab, do not need dose

chronic OACs should be kept on their therapy unless there are abso-

adjustments at this time. If possible, patients may be switched to

lute contraindications (such as active bleeding, severe thrombocy-

dabigatran, edoxaban, or betrixaban as the DOAC of choice if com-

topenia, planned procedure, or significant new drug interaction or

54

Alternatively,

other contraindications). To reduce new patient contacts within the

dose-adjusted VKAs with frequent International Normalized Ratio

anticoagulation clinic, it is important that all pharmacists review the

(INR) monitoring or parenteral anticoagulants may be a good option.

indication for anticoagulation and determine if a DOAC treatment

bined therapy with CYP3A4 inhibitor is prescribed.

could be clinically appropriate. Patients with long-term anticoagulation receiving a VKA should be considered for alternative therapies,

1.1.3 | Extended out-of-hospital VTE prophylaxis

such as DOACs or LMWH, or increasing the interval of INR monitoring to 12 weeks in stable patients on warfarin.59 Patients who are

Of all VTEs occurring in the community, at least half are related to

breastfeeding or who have mechanical valves, ventricular assist de-

55

vices, renal failure with a creatinine clearance <15 mL/min or rapidly

Thus, hospitalization of acutely ill patients is associated with an

worsening renal function, weight over 120 kg, gastric malabsorption

8-fold increase in VTE risk.55 Studies of medically ill patients have

disorders, or antiphospholipid antibody syndrome should be treated

shown the benefit of extended VTE prophylaxis in high-risk patient

with warfarin.

current or recent hospitalization for surgery or medical illness.

|
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3. Extended thromboprophylaxis: Patients hospitalized with COVID-

VTE risk factor

Points for the
risk score

Previous VTE

3

Thrombophiliab

2

Current lower limb paralysis or paresisc

2

Cancerd

2

Immobilizatione

1

ICU/CCU stay

1

Age > 60 y

1

Note: The interpretation of the score predicts VTE risk through 3 mo as
follows: score 0 = 0.4%; score 1 = 0.6%; score 2 = 1%; score 3 = 1.7%;
score 4 = 2.9%; score ≥ 5=7.2%.
CCU, coronary care unit; ICU, intensive care unit; RAM, risk assessment
model; VTE, venous thromboembolism.
a

A score of 0-1 constitutes low VTE risk; A score of 2-3 constitutes
moderate VTE risk; A score of ≥4 constitutes high VTE risk.

19, especially those with an IMPROVE VTE score of ≥4, elevated
D-dimer (>2× ULN), or over 60 years and without bleeding risk
factors, or recent ICU stay should be strongly considered for extended thromboprophylaxis up to 40 days after hospital discharge
with either lovenox 40 mg s.c. daily, rivaroxaban 10 mg p.o. daily,
or betrixaban 80 mg p.o. daily.
4. Routine empiric therapeutic dose of intravenous UFH or systemic
tissue plasminogen activator or routine use of inferior vena cava
filters: No current supporting evidence for its use without absolute indications.
5. Continuation of home antithrombotic medications or need of
chronic antithrombotics: Patients on antiplatelets or OACs should
be kept on their therapy unless there are absolute contraindications (such as active bleeding, severe thrombocytopenia, planned
procedure, or significant new drug interaction or other contraindications). DOACs are preferred over warfarin for treatment of

A congenital or acquired condition leading to an excess risk of
thrombosis.

VTE or atrial fibrillation due to decreased need for monitoring.

c

tiphospholipid antibody syndrome should be treated with warfa-

b

Leg falls to bed by 5 s, but has some effort against gravity (from
National Institutes of Health stroke scale).
d

May include active cancer (excluding nonmelanoma skin cancer) or a
history of cancer within 5 y.

e

Strict definition is complete immobilization confined to bed or
chair ≥ 7 d; modified definition is complete immobilization with or
without bathroom privileges ≥ 1 d.

Patients with mechanical valves, ventricular assist devices, or anrin, with extended periods for INR monitoring or drive-through
monitoring.
6. Patients on antiviral therapy, such as lopinavir/ritonavir: For
antiplatelet agents, certain antivirals, especially lopinavir/ritonavir, may potentiate CYP3A4 or P-gp inhibition, and as such
there may be reduction in clopidogrel effects and increased ef-

1.2 | Summary of key recommendations from
institutional protocols

fects of ticagrelor. Therefore, patients on these agents should
have them switched over to prasugrel if possible (unless contraindications such as prior stroke or transient ischemic attack).
Alternatively, platelet function studies (P2Y12 monitoring)

These interim institutional protocols are not intended to replace clin-

may also be considered. For OACs, if possible, patients may be

ical judgment and may not apply to all patients or clinical situations

switched to dabigatran, edoxaban, or betrixaban from apixaban

where antithrombotic therapy is needed.

and rivaroxaban as the DOACs of choice if combined therapy
with CYP3A4 inhibitor is prescribed. Alternatively, dose-ad-

1. Medical floor COVID-19–positive patients: LMWH at prophylactic or intermediate doses (ie, 40 mg s.c. daily or 40 mg s.c.

justed warfarin with frequent INR monitoring should be a good
option.

twice daily, especially for BMI > 30 kg/m2) as the preferred
agent over UFH, unless patients have severe renal insufficiency

R E L AT I O N S H I P D I S C LO S U R E

(CrCl < 30 or 15 mL/min). In patients with acute renal failure

KPC reports nothing to disclose. GM reports nonfinancial support

or chronic kidney disease with CrCl <15 mL/min or on dialysis,

from Aspen, personal fees from BMS/Pfizer, personal fees and non-

UFH 5000 units 3 times daily or 7500 units 3 times daily if

financial support from Bayer, and personal fees from LEO pharma,

2

BMI > 40 kg/m is recommended. We acknowledge the data

outside the submitted work. AJT reports an educational grant from

are not as robust for a BMI > 30 kg/m2 cutoff relative to

Janssen and research support from Janssen, BMS, Idorsia, and

40 kg/m2 BMI.

Daiichi Sankyo; and consulting for Recovery Force. ACS reports

2. Patients with severe COVID-19 requiring high-flow oxygen or

consulting fees from Bayer, BMS, Janssen, Boehringer Ingelheim,

ventilator: LMWH at prophylactic or intermediate doses (ie, 40 mg

Portola, and ATLAS group; and research grants from Janssen and

s.c. daily or 40 mg s.c. twice daily, especially for BMI > 30 kg/m2)

Boehringer Ingelheim.

as the preferred agent over UFH, should be utilized in ICU settings, with serious illness meeting sepsis-induced coagulopathy
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score of ≥4 or with markedly elevated D-dimer (>6× ULN). UFH
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dialysis.
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